Product Description
| Brand |
Beckman Coulter |
| Sample Type |
Serum/ Plasma |
| Pack Size |
2 x 50T |
| CAT No. |
D22920 |
Application
|
Infectious disease |
Beckman Coulter Access Anti-HBc IgM (CLIA) is a high-performance Chemiluminescent Immunoassay (CLIA) reagent designed for the qualitative detection of IgM antibodies to Hepatitis B Core Antigen (Anti-HBc IgM) in human serum and plasma. Access Anti-HBc IgM reagents plays a vital role in the diagnosis of acute Hepatitis B Virus (HBV) infection and helps identify recent HBV exposure. It is widely used alongside other hepatitis B serological markers for comprehensive HBV screening and clinical evaluation.
Advanced Chemiluminescence TechnologyThe BC Access Anti-HBc IgM employs Chemiluminescence Immunoassay (CLIA) technology, ensuring high sensitivity and specificity in detecting IgM antibodies related to Hepatitis B infection. This modern approach promotes accurate and timely diagnoses.
Fully Automatic and Real-Time OperationDesigned for convenience, the system operates fully automatically, delivering real-time results. Its compatibility with CLIA analyzers streamlines laboratory workflow and eliminates the risk of manual error, enhancing efficiency.
Ideal for Laboratories Across IndiaWith portability and suitability for various laboratory sizes, the BC Access Anti-HBc IgM (CLIA) is tailored to the needs of Indian dealers, distributors, and healthcare providers. Reliable storage conditions maintain its performance during transport and use.
FAQ's of BC Access Anti-HBc IgM (CLIA):
Q: How does the BC Access Anti-HBc IgM (CLIA) detect Hepatitis B Core IgM antibodies?
A: This system uses Chemiluminescence Immunoassay (CLIA) technology to qualitatively detect IgM antibodies against Hepatitis B Core Antigen. The test involves automatic analysis on a CLIA analyzer, providing high sensitivity and specificity.
Q: What are the main usage benefits of this CLIA-based assay?
A: The assay offers rapid, real-time results with minimal hands-on time, thanks to its automatic operation. Its portability and reliability are especially beneficial in laboratory settings demanding fast and accurate Hepatitis B diagnosis.
Q: When should laboratories use the BC Access Anti-HBc IgM (CLIA) test?
A: Laboratories should use this test when there is a need to detect recent or acute Hepatitis B infection, as the presence of IgM antibodies indicates early-stage or active infection.
Q: Where can the BC Access Anti-HBc IgM (CLIA) system be deployed?
A: The assay is intended for laboratory settings and is suitable for use by dealers, distributors, exporters, manufacturers, suppliers, traders, and wholesalers throughout India.
Q: What is the recommended storage condition for this product?
A: To maintain efficacy, store the system between 2 to 10 degrees Celsius, ensuring consistent performance and prolonged shelf life.
Q: How is the test process carried out using this product?
A: The testing process is automatic. Place the sample in the CLIA analyzer, and the instrument performs the analysis, detecting the presence of anti-HBc IgM and providing results swiftly and accurately.